Company Filing History:
Years Active: 2017-2023
Title: Guro Elisabeth Lind: Innovator in Colorectal Cancer Detection
Introduction
Guro Elisabeth Lind is a prominent inventor based in Oslo, Norway. She has made significant contributions to the field of molecular biology, particularly in the detection and quantification of nucleic acids. With a total of 5 patents, her work has the potential to impact cancer diagnostics and treatment.
Latest Patents
One of her latest patents focuses on PCR controls. This invention provides a method for quantifying a target nucleic acid using a combination of genes, specifically SYT10, EPHA3, PLEKHF1, and KBTBD4, known as the 4Plex. This combination serves as a control for nucleic acid quantification, particularly useful in methylation-specific droplet digital PCR. Another significant patent relates to methods and biomarkers for the analysis of colorectal cancer. This invention includes various protein biomarkers for detecting colorectal cancer in biological samples, such as tissue, blood, and stool samples. These methods aim to improve the prognosis for colorectal cancer patients and enhance companion diagnostics.
Career Highlights
Guro Elisabeth Lind is affiliated with Oslo Universitetssykehus HF, where she continues her research and development in the field of cancer diagnostics. Her innovative approaches have garnered attention in the scientific community, contributing to advancements in medical technology.
Collaborations
Guro collaborates with esteemed colleagues, including Ragnhild A Lothe and Rolf Inge Skotheim. These partnerships enhance her research efforts and expand the impact of her inventions.
Conclusion
Guro Elisabeth Lind is a trailblazer in the field of molecular diagnostics, particularly in colorectal cancer detection. Her innovative patents and collaborations position her as a key figure in advancing cancer research and improving patient outcomes.